TIP751: Mastermind Q3, 2025: Uber, Merck, and Bath & Body Works
Episode
94 min
Read time
2 min
Topics
Health & Wellness, Relationships, Investing
AI-Generated Summary
Key Takeaways
- ✓Uber's Network Economics: The company operates a supply-driven two-sided marketplace requiring critical mass of drivers first before demand materializes. This creates strong local network effects that are difficult to disrupt once established at scale, though effects remain city-specific rather than global, requiring market-by-market conquest against local competitors like Grab in Southeast Asia.
- ✓Autonomous Vehicle Integration: Uber maintains competitive advantages over pure AV players like Waymo through flexible supply management—human drivers can be called during surge periods while AVs require constant capital deployment. The company's matching algorithm technology and ability to offer both human and autonomous options positions it as potential infrastructure partner rather than displacement target for AV manufacturers.
- ✓Merck's Patent Cliff Strategy: Keytruda generates $29.5B annually (nearly half of Merck's revenue) with 2028 patent expiration creating 3-5% annual revenue decline rather than immediate cliff due to biosimilar competition dynamics. Management pursues subcutaneous delivery extension, $10B Verona acquisition for COPD drugs, and late-stage pipeline development to offset losses by 2032.
- ✓Bath & Body Works Valuation Disconnect: The company trades at 7.5x earnings and 6.3x price-to-cash flow versus historical 8x average, generating $750M free cash flow (12% yield on market cap). Management reduced share count from 280M to 212M since 2021 peak, demonstrating capital allocation discipline during 40% stock price decline from all-time highs.
- ✓Pharmaceutical Sector Positioning: Healthcare trades at 25-year valuation lows relative to broader market, similar to late 1990s setup that preceded strong multi-year performance. Merck's 31% operating margin leads pharma industry while trading at 12x earnings versus peer average of 18x, offering 4% dividend yield during valuation normalization period with limited downside risk.
What It Covers
Stig Brodersen, Tobias Carlisle, and Hari Ramachandra analyze three investment opportunities: Uber's mobility and delivery ecosystem at $190B market cap, Merck's oncology dominance facing Keytruda patent expiration in 2028, and Bath & Body Works' fragrance retail business trading at 7.5x earnings.
Key Questions Answered
- •Uber's Network Economics: The company operates a supply-driven two-sided marketplace requiring critical mass of drivers first before demand materializes. This creates strong local network effects that are difficult to disrupt once established at scale, though effects remain city-specific rather than global, requiring market-by-market conquest against local competitors like Grab in Southeast Asia.
- •Autonomous Vehicle Integration: Uber maintains competitive advantages over pure AV players like Waymo through flexible supply management—human drivers can be called during surge periods while AVs require constant capital deployment. The company's matching algorithm technology and ability to offer both human and autonomous options positions it as potential infrastructure partner rather than displacement target for AV manufacturers.
- •Merck's Patent Cliff Strategy: Keytruda generates $29.5B annually (nearly half of Merck's revenue) with 2028 patent expiration creating 3-5% annual revenue decline rather than immediate cliff due to biosimilar competition dynamics. Management pursues subcutaneous delivery extension, $10B Verona acquisition for COPD drugs, and late-stage pipeline development to offset losses by 2032.
- •Bath & Body Works Valuation Disconnect: The company trades at 7.5x earnings and 6.3x price-to-cash flow versus historical 8x average, generating $750M free cash flow (12% yield on market cap). Management reduced share count from 280M to 212M since 2021 peak, demonstrating capital allocation discipline during 40% stock price decline from all-time highs.
- •Pharmaceutical Sector Positioning: Healthcare trades at 25-year valuation lows relative to broader market, similar to late 1990s setup that preceded strong multi-year performance. Merck's 31% operating margin leads pharma industry while trading at 12x earnings versus peer average of 18x, offering 4% dividend yield during valuation normalization period with limited downside risk.
Notable Moment
Hari describes riding in a Waymo autonomous vehicle in San Francisco, noting the seamless experience with step-by-step parking directions, automatic passenger recognition, and personalized music selection. The technology demonstration convinced him autonomous driving has moved from laboratory concept to scalable product, though distribution and fleet economics remain unresolved competitive factors.
Episode Transcript
You're listening to TIP. I always look forward to recording our mastermind episodes with my good friends Tobias Carlisle and Hari Ramachandra. These are some of my favorite conversations because once a quarter, we each bring a stock to the group. And together we explore both the bull and the bear cases. It's never about just shielding a company we like. It's really about testing our ideas, asking the hard questions, and seeing where we might be wrong. Over the years, I found this format not only makes me a better investor, but also keeps me grounded and curious. And I really hope it'll do the same for you. In today's episode, I'll be pitching Uber, the world's largest ride hailing company. It's a business that many of us use frequently. But when you dig into the numbers, you see there's a fascinating story about scale, networking effects, and how the company is building an expanding ecosystem well beyond just rides. Tobias is sharing his thoughts on Bath and Body Works, which is category leader in home and personal fragrance. It's one of those companies that might fly under the radar for many investors, yet it has an incredible strong brand recognition, customer loyalty, and generates a ton of free cash flow. And finally, Harish PEG is Merck, one of the biggest names in pharmaceuticals. Merck is best known today for a blockbuster oncology drug, which has changed the landscape of cancer treatment. But like many other pharma companies, there's a challenge ahead with the Lumen patent clef, and we'll be digging into what that means for long term investors. So grab a cup of coffee, get comfortable, and join us as we dive into three very different businesses. We'll cover what makes them compelling, risk to look out for, and hopefully, leave you with a few new ideas for your own investing journey. Since 2014 and through more than 180,000,000 downloads, we've studied the financial markets and read the books that influence self made billionaires the most. We keep you informed and prepared for the unexpected. Now for your host, Stake Brodersen. Welcome to The Investor's Podcast. I'm your host, Stig Brodersen. Today, as always, I'm here with Toby and Hari. How are you today, gents? Stig Brodersen (one zero three:forty one): Hi, fellas. Good to see you. Thanks for having me, Stig. Stig Brodersen (one zero three:forty five): Yeah. Good to see you both. Thanks for having us. Stig Brodersen (one zero three:forty five): Amazing. And gents, I'm going to, shamelessly, I'm just going to go straight to the pits here. My pick is Uber, certainly a stock I think most in the audience have heard about before, dollars 190,000,000,000 in market cap. The first time the stock really came on my radar was not as a service, I should say, but as a stock worth investing in, was whenever I listened to this episode that my co hosts, Daniel and Sean, on the intrinsic value podcast, whenever …
Get the full transcript (16,767 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 91-minute episode.
Get We Study Billionaires summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from We Study Billionaires
TIP844: Uber (UBER): The Autonomy Referendum — Is Mr. Market Completely Wrong? w/ Daniel Mahncke & Shawn O’Malley
Sep 6 · 66 min
Cognitive Revolution
AI:AM Highlights: Welcome to the AGI Era
Sep 5
More from We Study Billionaires
TIP843: AppLovin (APP): The 30-Bagger Down More Than Half w/ Kyle Grieve & Shawn O'Malley
Sep 3 · 90 min
Investing for Beginners
Dissecting Capital One, Netflix, and Wall Street's Favorite Metrics
Aug 27
More from We Study Billionaires
We summarize every new episode. Want them in your inbox?
TIP844: Uber (UBER): The Autonomy Referendum — Is Mr. Market Completely Wrong? w/ Daniel Mahncke & Shawn O’Malley
TIP843: AppLovin (APP): The 30-Bagger Down More Than Half w/ Kyle Grieve & Shawn O'Malley
TIP842: Comfort Systems USA (FIX): The Five-Bagger We Passed On w/ Kyle Grieve & Shawn O'Malley
TIP841: Palantir – Palantir is Cheaper than I Thought! w/ Daniel Mahncke & Shawn O’Malley
TIP840: CATL: Powering EVs, Power Grids, and AI w/ Stig Brodersen, Manish Karira & Ralph Summerford
Similar Episodes
Related episodes from other podcasts
Cognitive Revolution
Sep 5
AI:AM Highlights: Welcome to the AGI Era
Investing for Beginners
Aug 27
Dissecting Capital One, Netflix, and Wall Street's Favorite Metrics
Pivot
Aug 18
USS Lincoln Fallout, Spotlight on Natalie Harp, and Press Secretary Succession
All-In with Chamath, Jason, Sacks & Friedberg
Aug 14
Anthropic's $2T IPO, Zuck's AI Manifesto, Nvidia's $500B AI Bet, Grok's Comeback
Investing for Beginners
Aug 3
Birdseye View ASTS: Moonshot Potential vs. Financial Reality
Explore Related Topics
This podcast is featured in Best Investing Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into We Study Billionaires.
Every Monday, we deliver AI summaries of the latest episodes from We Study Billionaires and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime